Cargando…

Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors

BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Maximilian, Brunner, Patrick, Geissmann, Leonie, Gürtler, Martin, Schwager, Fabienne, Waldis, Rowena, Vogel, Marc, Wiesbeck, Gerhard A., Dürsteler, Kenneth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980546/
https://www.ncbi.nlm.nih.gov/pubmed/35392381
http://dx.doi.org/10.3389/fpsyt.2022.846834
_version_ 1784681418998153216
author Meyer, Maximilian
Brunner, Patrick
Geissmann, Leonie
Gürtler, Martin
Schwager, Fabienne
Waldis, Rowena
Vogel, Marc
Wiesbeck, Gerhard A.
Dürsteler, Kenneth M.
author_facet Meyer, Maximilian
Brunner, Patrick
Geissmann, Leonie
Gürtler, Martin
Schwager, Fabienne
Waldis, Rowena
Vogel, Marc
Wiesbeck, Gerhard A.
Dürsteler, Kenneth M.
author_sort Meyer, Maximilian
collection PubMed
description BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment (OAT) on SDs remains unclear, with some studies demonstrating an improvement after methadone maintenance treatment (MMT) initiation. However, no studies on the prevalence and predictors of SDs in heroin-assisted treatment (HAT) exist to date. METHODS: A cross-sectional study was conducted with patients from a MMT center (n = 57) and a center specializing in HAT (n = 47). A control group of patients with mild transient illnesses (n = 67) was recruited from a general practitioner (GP). The International Index of Erectile Function, the Female Sexual Function Index, as well as measurements for psychological distress, depressive state, nicotine dependence, and high-risk alcohol use were employed. Patients also completed a self-designed questionnaire on help-seeking behavior regarding sexual health. Mann-Whitney-U tests and chi-square tests were performed for group comparisons and binary logistic regression models were calculated. RESULTS: Twenty-five percent of the GP sample (n = 17), 70.2% (n = 40) of the MMT sample, and 57.4% (n = 27) of the HAT sample suffered from SDs at the time of study conduction. OAT patients differed significantly from GP patients in depressive state, high-risk alcohol use, nicotine dependence, and psychological distress. Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. No differences between OAT and GP patients were found regarding help-seeking behavior. DISCUSSION: Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. It remains unclear whether SDs are caused by opioid intake itself or result from other substance-use related lifestyle factors, that were not controlled for in this study. A lack of help-seeking behavior was observed in our sample, underlining the importance of clinicians proactively inquiring about the sexual health of their patients. CONCLUSION: The high prevalence of SDs observed in MMT does not differ from the prevalence in HAT. Clinicians should actively inquire about their patients’ sexual health in GP and OAT centers alike.
format Online
Article
Text
id pubmed-8980546
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89805462022-04-06 Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors Meyer, Maximilian Brunner, Patrick Geissmann, Leonie Gürtler, Martin Schwager, Fabienne Waldis, Rowena Vogel, Marc Wiesbeck, Gerhard A. Dürsteler, Kenneth M. Front Psychiatry Psychiatry BACKGROUND AND AIMS: Sexual dysfunctions (SDs) show a marked impact on a person’s general wellbeing. Several risk-factors like physical and mental illnesses as well as alcohol and tobacco use have to date been identified to contribute to the occurrence of SDs. The impact of opioid-agonist treatment (OAT) on SDs remains unclear, with some studies demonstrating an improvement after methadone maintenance treatment (MMT) initiation. However, no studies on the prevalence and predictors of SDs in heroin-assisted treatment (HAT) exist to date. METHODS: A cross-sectional study was conducted with patients from a MMT center (n = 57) and a center specializing in HAT (n = 47). A control group of patients with mild transient illnesses (n = 67) was recruited from a general practitioner (GP). The International Index of Erectile Function, the Female Sexual Function Index, as well as measurements for psychological distress, depressive state, nicotine dependence, and high-risk alcohol use were employed. Patients also completed a self-designed questionnaire on help-seeking behavior regarding sexual health. Mann-Whitney-U tests and chi-square tests were performed for group comparisons and binary logistic regression models were calculated. RESULTS: Twenty-five percent of the GP sample (n = 17), 70.2% (n = 40) of the MMT sample, and 57.4% (n = 27) of the HAT sample suffered from SDs at the time of study conduction. OAT patients differed significantly from GP patients in depressive state, high-risk alcohol use, nicotine dependence, and psychological distress. Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. No differences between OAT and GP patients were found regarding help-seeking behavior. DISCUSSION: Age, depressive state, and opioid dependence predicted the occurrence of SDs in the total sample. It remains unclear whether SDs are caused by opioid intake itself or result from other substance-use related lifestyle factors, that were not controlled for in this study. A lack of help-seeking behavior was observed in our sample, underlining the importance of clinicians proactively inquiring about the sexual health of their patients. CONCLUSION: The high prevalence of SDs observed in MMT does not differ from the prevalence in HAT. Clinicians should actively inquire about their patients’ sexual health in GP and OAT centers alike. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980546/ /pubmed/35392381 http://dx.doi.org/10.3389/fpsyt.2022.846834 Text en Copyright © 2022 Meyer, Brunner, Geissmann, Gürtler, Schwager, Waldis, Vogel, Wiesbeck and Dürsteler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Meyer, Maximilian
Brunner, Patrick
Geissmann, Leonie
Gürtler, Martin
Schwager, Fabienne
Waldis, Rowena
Vogel, Marc
Wiesbeck, Gerhard A.
Dürsteler, Kenneth M.
Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title_full Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title_fullStr Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title_full_unstemmed Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title_short Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice—Identifying Group Differences and Predictors
title_sort sexual dysfunctions in patients receiving opioid agonist treatment and heroin-assisted treatment compared to patients in private practice—identifying group differences and predictors
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980546/
https://www.ncbi.nlm.nih.gov/pubmed/35392381
http://dx.doi.org/10.3389/fpsyt.2022.846834
work_keys_str_mv AT meyermaximilian sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT brunnerpatrick sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT geissmannleonie sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT gurtlermartin sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT schwagerfabienne sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT waldisrowena sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT vogelmarc sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT wiesbeckgerharda sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors
AT durstelerkennethm sexualdysfunctionsinpatientsreceivingopioidagonisttreatmentandheroinassistedtreatmentcomparedtopatientsinprivatepracticeidentifyinggroupdifferencesandpredictors